Supplementary Figure S6 from Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies
Year: 2023
Type: supplementary-materials
Abstract: IHC staining of WM3965 PDX tumors treated with indicated compounds after 3 day of dosing and 4 hours post last dose for Ki67 (upper row) and cleaved caspase 3 (lower row).
Authors: Clemens Krepler, Min Xiao, Katrin Sproesser, Patricia A. Brafford, Batool Shannan, Marilda Beqiri, Qin Liu, Wei Xu, Bradley Garman, Katherine L. Nathanson, Xiaowei Xu, Giorgos C. Karakousis, Gordon B. Mills, Yiling Lu, Tamer A. Ahmed, Poulikos I. Poulikakos, Giordano Caponigro, Markus Boehm, Malte Peters, Lynn M. Schuchter, Ashani T. Weeraratna, Meenhard Herlyn
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4361918111